Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 1.00 |
| ▸ | DRD3 | P35462 | 18/20 | 1.00 |
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7504936 | 0.91 | DRD4 (1.00) | DRD4DRD3DRD2HTR1AHRH4 | |
| SCHEMBL30041650 | 0.88 | DRD2 (0.79) | DRD4DRD3DRD2HTR1AADRA2A | |
| SCHEMBL23932544 | 0.88 | DRD2 (0.79) | DRD4DRD3DRD2HTR1AADRA2A | |
| SCHEMBL5065047 | 0.88 | DRD4 (1.00) | DRD4DRD3DRD2HTR1AADRA2A | |
| SCHEMBL28962388 | 0.83 | DRD4 (0.72) | DRD4DRD3DRD2HTR1AADRA2A | |
| SCHEMBL8682915 | 0.82 | HRH4 (0.69) | DRD4DRD3DRD2HTR1AHRH4 | |
| SCHEMBL30041328 | 0.82 | HRH4 (0.69) | DRD4DRD3DRD2HTR1AHRH4 | |
| SCHEMBL5021447 | 0.79 | DRD4 (0.65) | DRD4DRD3DRD2HTR1AADRA2A | |
| SCHEMBL7504732 | 0.75 | DRD2 (1.00) | DRD4DRD3DRD2HTR1A | |
| SCHEMBL7495498 | 0.75 | DRD2 (1.00) | DRD4DRD3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-9827242-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9259423-B2 | Method of treatment for mental disorders | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20130018056-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2013-01-17 | — | — | US | disclosed |
| US-8258139-B2 | Method of treatment for mental disorders | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-04 | — | — | US | disclosed |
| WO-2012063513-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | Sumitomo Pharma Co., Ltd. (JP) | 2012-05-10 | — | — | US | disclosed |
| EP-1222167-A2 | METHOD FOR PRODUCING INDOLE DERIVATIVES ON A SOLID PHASE | MERCK PATENT GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001023353-A2 | METHOD FOR PRODUCING INDOLE DERIVATIVES ON A SOLID PHASE | MERCK PATENT GMBH (DE) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193205-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD3 8/4885DRD2 6/4885 |
| US-20130018056-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD3 8/4885DRD2 6/4885 |
| US-20190022091-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD3 8/4885DRD2 6/4885 |
| US-20120115879-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD3 8/4885DRD2 6/4885 |
| US-20160129000-A1 | METHOD OF TREATMENT FOR MENTAL DISORDERS | DRD4, HTR4, SLC6A3 | DRD4 1/4885DRD3 8/4885DRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.